Zoster Recombinant Vaccine: Efficacy, Safety, and Duration

The recombinant zoster vaccine, sold under the brand name Shingrix, is a two-dose vaccine designed to prevent shingles (herpes zoster) and its complications in adults aged 50 and older. Unlike the older live attenuated vaccine it replaced, the recombinant version uses a single viral protein paired with a potent adjuvant to stimulate immunity, and it works in people whose immune systems are too compromised for a live virus vaccine. In clinical trials, it prevented shingles in roughly 97% of adults in their fifties and maintained strong protection even a decade later, though the story gets more nuanced in real-world use.

What the Vaccine Contains and How It Works

The recombinant zoster vaccine contains a lab-made copy of glycoprotein E (gE), the most abundant protein on the surface of varicella-zoster virus. Your immune system already recognizes this protein from the original chickenpox infection, but the vaccine gives it a much stronger refresher than the aging immune system can manage on its own. The key ingredient that makes this refresher so effective is an adjuvant called AS01B, which ramps up both antibody production and T-cell responses against gE.¹ Because the vaccine contains no live virus, it cannot cause chickenpox or shingles, and it can be given to people on immunosuppressive therapy.

The reason a shingles-specific vaccine is needed at all has to do with how the virus behaves after chickenpox. Varicella-zoster virus never leaves your body. After the initial infection, it hides in nerve cells along the spine and skull, held in check by your immune system. As you age, the T cells that keep the virus dormant decline in number and function. Conditions that further weaken immunity, such as cancer treatment, organ transplant drugs, or HIV, accelerate this process and raise the risk of reactivation. When the virus wakes up, it travels along a nerve to the skin, producing the painful blistering rash known as shingles.

Efficacy in Clinical Trials

The vaccine’s headline numbers come from two large phase 3 trials known as ZOE-50 and ZOE-70, which together enrolled tens of thousands of adults. In ZOE-50, which included adults aged 50 and older, overall vaccine efficacy against shingles was about 97%, with efficacy between roughly 97% and 98% across all age groups studied.² Combined data from both trials confirmed that protection exceeded 90% in every age group from 50 upward, including people in their seventies and eighties.³ That consistency across ages is a meaningful improvement over the older live vaccine, whose protection dropped sharply in older recipients.

Sub-group analyses showed these results held across different populations. In Asian participants from the same two trials, two doses of the recombinant vaccine still demonstrated over 90% efficacy against shingles.⁴

How Long Protection Lasts

Clinical trial participants have now been followed for over a decade, and the data show a slow, gradual decline in protection rather than a sudden drop-off. A long-term follow-up study found that from about six years to nearly ten years after vaccination, efficacy against shingles was around 82%. When measured from one month after the second dose all the way out to roughly ten years, cumulative efficacy was about 89%. Annual estimates stayed above 83% through year eight, then dipped to around 73% in years nine and ten.⁵

The final analysis of that follow-up study extended the picture even further. In adults who were at least 50 when first vaccinated, efficacy was about 80% during the extended follow-up period. Protection against the most feared complication, postherpetic neuralgia (persistent nerve pain after shingles), was about 88%. Even in the eleventh year after vaccination, efficacy against shingles was sustained at around 82%. Immune measurements showed that both antibody levels and T-cell responses settled at a plateau well above pre-vaccination levels and stayed there.⁶ A systematic review and meta-analysis characterized this pattern as slow waning over a median follow-up of about ten years.⁷

One intriguing finding from immunology research helps explain why protection holds up so well. The vaccine appears to recruit naive T cells (immune cells that have never encountered the virus before) into the response, not just reactivate existing memory cells. The frequency of these newly recruited naive cells correlated strongly with the number of long-lasting T-cell clones still detectable years later, suggesting the vaccine builds a fresh reserve of immune defenders rather than simply boosting a fading memory.⁸

Protection Against Postherpetic Neuralgia and Eye Involvement

Shingles itself is painful, but the complications can be worse. Postherpetic neuralgia, nerve pain that persists for months or years after the rash heals, is the most common serious consequence, and it becomes more likely with age. A large real-world study found that the vaccine’s effectiveness against postherpetic neuralgia was about 87% for fully vaccinated adults and 69% for those who received only one dose. Even among people who did develop shingles despite vaccination, the risk of progressing to postherpetic neuralgia was about 47% lower compared with unvaccinated individuals. The study also found that effectiveness against postherpetic neuralgia was somewhat lower in people who had received corticosteroids before vaccination (about 75%) compared with those who had not (about 88%).⁹

Shingles that affects the eye, called herpes zoster ophthalmicus, can cause serious vision problems. The recombinant vaccine outperformed the older live vaccine in preventing this as well. In a study of people with chronic inflammatory skin conditions, a population already at elevated risk, the recombinant vaccine significantly reduced the risk of ophthalmic zoster and other complicated forms of shingles compared with the live vaccine.¹⁰

Side Effects and What to Expect

The recombinant zoster vaccine is noticeably more reactive than many vaccines adults are used to receiving. In pooled data from the two pivotal trials, about 78% of vaccine recipients reported injection-site pain, compared with 11% in the placebo group. Roughly 45% reported muscle pain, a similar proportion reported fatigue, and about 38% reported headache. Severe (grade 3) pain at the injection site occurred in about 6% of recipients. The good news is that most symptoms were mild to moderate and resolved within two to three days. The intensity did not get substantially worse after the second dose compared with the first.¹¹

A post hoc analysis of reactogenicity patterns found that among people who did not experience a specific side effect after their first dose, the vast majority (73–92%) did not experience it after the second dose either. Among those who did have a grade 3 reaction after the first dose, roughly two-thirds to nine-tenths reported the same side effect at a lower intensity after the second dose. So while a rough first dose does raise your chances of a reaction the second time, the second dose is more likely to be milder than a repeat of the worst-case scenario.

The Guillain-Barré Signal

Post-marketing surveillance flagged a potential link between the recombinant zoster vaccine and Guillain-Barré syndrome (GBS), a rare autoimmune condition that causes muscle weakness and sometimes paralysis. A study of Medicare beneficiaries found a roughly two- to three-fold increased risk of GBS in the 42 days following vaccination compared with a control period, translating to an estimated three extra cases of GBS per million doses administered in adults aged 65 and older.¹² In March 2021, the FDA added a warning about GBS to the vaccine’s labeling.¹³

The picture remains uncertain, however. A separate active surveillance study covering roughly 648,000 doses found no statistically significant elevated risk of GBS for vaccine recipients when compared with concurrent well-visit comparators. After manual chart review of suspected cases, many were reclassified as not true incident GBS, and the final risk ratios were close to 1.0 with wide confidence intervals.¹⁴ The overall VAERS disproportionality analysis also did not detect a significant GBS signal.¹⁵ In practice, even the highest estimates put the absolute risk at a handful of cases per million doses. Health authorities have concluded that the benefits of avoiding shingles and its complications outweigh this rare risk, but the warning ensures that both patients and clinicians can factor it into the conversation.

Use in Immunocompromised People

One of the biggest advantages of the recombinant vaccine over the old live vaccine is that it can be given to people with weakened immune systems. The live vaccine was explicitly contraindicated in this group because of the theoretical risk that the weakened virus could cause disease. The recombinant vaccine contains no live virus, so that concern does not apply, and these patients often need protection the most.

Safety data pooled from six clinical trials in immunocompromised populations, including people with HIV, blood cancers, solid organ transplants, and those on immunosuppressive therapy, found no new safety concerns. Injection-site reactions were more common in the vaccine group than placebo, just as in the general population trials, but rates of serious adverse events and deaths were similar between groups.¹⁶

In kidney transplant recipients, who take drugs that suppress the immune system to prevent organ rejection, the vaccine produced strong immune responses. About 80% of vaccinated transplant recipients mounted a measurable antibody response, and antibody levels remained well above baseline at 13 months after vaccination. T-cell responses were also significantly elevated. No biopsy-proven kidney rejections occurred between the first dose and 30 days after the last dose in either the vaccine or placebo group, addressing a critical safety question for this population.¹⁷

Real-World Effectiveness and the Two-Dose Problem

Clinical trial efficacy and real-world effectiveness are different measures, and the gap matters here. In a large real-world study, the adjusted effectiveness of two doses was about 76%, and a single dose provided roughly 64% protection. After two doses, effectiveness held fairly steady: about 79% in the first year, 75% in the second, and 73% in the third and fourth years.¹⁸ Those numbers are lower than the 97% from the trials, partly because real-world populations include sicker people, people who got their doses at irregular intervals, and people who only completed one of two doses.

That last point is a persistent challenge. A study of more than 726,000 adults found that about 72% completed the two-dose series within the recommended timeframe, and 86% eventually completed it within two years. But that still means a sizable minority never returns for the second shot. Younger adults, people with lower incomes, and those with commercial insurance rather than Medicare were less likely to complete the series.¹⁹ A single dose still provides meaningful protection, but the second dose matters for durability and for protection against complications. In patients with rheumatoid arthritis, for instance, those who completed both doses had a significantly lower risk of complicated shingles and all-cause mortality compared with single-dose recipients.²⁰

Getting Vaccinated Alongside Other Shots

Many adults eligible for the recombinant zoster vaccine are also due for flu shots, pneumococcal vaccines, or COVID-19 boosters. The practical question of whether these can be given at the same visit has been studied repeatedly. When co-administered with the 13-valent pneumococcal conjugate vaccine, the recombinant zoster vaccine produced immune responses that were non-inferior to giving the vaccines separately, and side effects were consistent with each vaccine’s known profile.²¹ A broader overview of co-administration trials confirmed this pattern across multiple vaccine pairings, with one caveat: co-administration with the 23-valent pneumococcal polysaccharide vaccine led to somewhat higher rates of shivering and fever (about 16–21%) compared with giving them separately (about 7% each).²²

Post-marketing safety surveillance of co-administration with influenza vaccines found no new or unexpected safety concerns beyond the known side-effect profiles of each individual vaccine.²³ So if you are offered the shingles vaccine at the same visit as your annual flu shot, there is no immunological reason to schedule a separate trip.

Cost-Effectiveness and Who Benefits Most

The recombinant zoster vaccine is not cheap. In the United States, the two-dose series runs several hundred dollars at retail, though most insurance plans and Medicare Part D cover it. A cost-effectiveness analysis found that vaccination was cost-effective for adults aged 60 and older using standard economic thresholds, but not at age 50. The cost per quality-adjusted life year gained was roughly $161,000 at age 50, dropping to about $31,000 at age 60 and $16,000 at age 70. The analysis estimated that vaccination becomes cost-effective at approximately age 54.²⁴ A broader review of cost-effectiveness studies across multiple countries found that the vaccine was cost-effective in most analyses, though results varied depending on assumptions about how long protection lasts.²⁵

The takeaway is that if you are in your fifties, you are eligible for the vaccine and it will protect you, but the health-economic argument strengthens considerably as you get older. The risk of shingles itself rises sharply with age, so the benefit of prevention becomes proportionally larger.

Vaccination After a Shingles Episode

Having shingles once does not guarantee you will not get it again. Recurrence rates vary, but the risk is real enough that vaccination is recommended even for people who have already had an episode. The question is timing. A study of immune responses to zoster vaccination found that vaccinating at least one year after a shingles episode produced immune responses similar to those seen in people who had not recently had shingles.²⁶ Current U.S. guidelines generally recommend waiting until the acute shingles episode has resolved before getting vaccinated. There is no strict minimum waiting period endorsed by the CDC, but given the immunogenicity data, many clinicians advise waiting several months to a year to let the natural immune boost from the illness subside before adding the vaccine’s stimulus on top of it.

How the Recombinant Vaccine Compares with the Old Live Vaccine

The live attenuated zoster vaccine (Zostavax) was the first shingles vaccine approved, in 2006. Its efficacy in clinical trials was about 51% overall and declined substantially in older age groups, dropping to around 38% in people over 70. By contrast, the recombinant vaccine maintained above 90% efficacy even in the oldest groups studied. The live vaccine’s protection also waned faster, fading considerably within five to eight years. In real-world head-to-head comparisons, people who received the recombinant vaccine had about 35–39% lower risk of shingles than those who had received the live vaccine, along with lower rates of postherpetic neuralgia and ophthalmic zoster.²⁷ The live vaccine was discontinued in the United States in 2020 and is no longer available. If you received the old vaccine years ago, current guidelines recommend getting the recombinant series as well, since the newer vaccine provides stronger and longer-lasting protection.